| Date Filed | Type | Description |
| 07/10/2023 |
4
| Korenberg Matthew E (PRESIDENT & CHIEF OPERATING) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 376 shares
@ $56.78, valued at
$21.3k
|
|
| 02/27/2023 |
4
| Korenberg Matthew E (President & COO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 9,069 shares
@ $0
Granted 24,628 options to buy
@ $75.09, valued at
$1.8M
|
|
| 12/30/2022 |
4
| Korenberg Matthew E (President & COO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 3,859 shares
@ $66.29, valued at
$255.8k
|
|
| 12/15/2022 |
4
| Korenberg Matthew E (President & COO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 14,000 shares
@ $0
Granted 30,000 options to buy
@ $63.62, valued at
$1.9M
|
|
| 12/01/2022 |
4
| Korenberg Matthew E (President & COO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 3,593 shares
@ $72.9, valued at
$261.9k
|
|
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/04/2022 |
4
| Korenberg Matthew E (Director) has filed a Form 4 on Qualigen Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $0.5136, valued at
$20.5k
|
|
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/16/2022 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 906 shares
@ $123.68, valued at
$112.1k
Paid exercise price by delivering 969 shares
@ $123.68, valued at
$119.8k
Paid exercise price by delivering 1,532 shares
@ $123.68, valued at
$189.5k
|
|
| 01/28/2022 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 4,803 shares
@ $0
Granted 6,848 shares
@ $0
Paid exercise price by delivering 1,319 shares
@ $113.68, valued at
$149.9k
Paid exercise price by delivering 2,309 shares
@ $113.68, valued at
$262.5k
|
|
| 07/02/2021 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 247 shares
@ $85.9095, valued at
$21.2k
|
|
| 02/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/27/2021 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 2,305 shares
@ $0
Paid exercise price by delivering 671 shares
@ $156.01, valued at
$104.7k
Granted 4,803 shares
@ $0
Paid exercise price by delivering 1,440 shares
@ $156.01, valued at
$224.7k
|
|
| 07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2020 |
4
| Korenberg Matthew E (Director) has filed a Form 4 on Qualigen Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $5.13, valued at
$256.5k
|
|
| 05/27/2020 |
3
| Korenberg Matthew E (Director) has filed a Form 3 on Qualigen Therapeutics, Inc. |
| 04/24/2020 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 354 shares
@ $120.86, valued at
$42.8k
Paid exercise price by delivering 377 shares
@ $120.86, valued at
$45.6k
Paid exercise price by delivering 435 shares
@ $120.86, valued at
$52.6k
|
|
| 02/18/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/26/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/23/2019 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Bought options to buy
@ $248.48, valued at
$0 |
|
| 09/03/2019 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Bought 500 shares
@ $86.1815, valued at
$43.1k
|
|
| 07/02/2019 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 182 shares
@ $97.0275, valued at
$17.7k
|
|
| 02/13/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/25/2019 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 2,418 shares
@ $0
Paid exercise price by delivering 713 shares
@ $111.78, valued at
$79.7k
Granted 2,230 shares
@ $0
Paid exercise price by delivering 612 shares
@ $111.78, valued at
$68.4k
|
|
| 08/29/2018 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 18,357 shares
@ $256.6901, valued at
$4.7M
Exercised 11,540 options to buy
@ $85.79, valued at
$990k
|
|
| 08/07/2018 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 836 shares
@ $226.74, valued at
$189.6k
|
|
| 07/03/2018 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 180 shares
@ $117.8355, valued at
$21.2k
|
|
| 03/06/2018 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 3,074 shares
@ $0
Granted 2,004 shares
@ $0
Paid exercise price by delivering 550 shares
@ $165.87, valued at
$91.2k
Granted 16,050 options to buy
@ $159.01, valued at
$2.6M
|
|
| 02/16/2018 |
4
| Korenberg Matthew E (EVP,Finance & Strategy and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 354 shares
@ $157.18, valued at
$55.6k
Paid exercise price by delivering 326 shares
@ $157.18, valued at
$51.2k
|
|
| 12/29/2017 |
4
| Korenberg Matthew E (VP, Finance and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 3,750 shares
@ $0
Paid exercise price by delivering 1,530 shares
@ $138.66, valued at
$212.1k
|
|
| 11/17/2017 |
4
| Korenberg Matthew E (VP, Finance and CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 6,559 shares
@ $142.63, valued at
$935.5k
|
|
|